Login
$GRAL
$108.50 +$2.90 (2.75%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Robert Ragusa Also a director
Chief Executive Officer and Director
66 Not stated Not stated $8,094,440
Joshua Ofman Also a director
Chief Executive Officer
Title from the Form 4 dated Oct 15, 2026
62 Not stated Not stated $4,318,592
Aaron Freidin
Chief Financial Officer
47 Since 2021
5 years
2016 $3,131,535
Andrew John Partridge
Chief Growth Officer
Title from the Form 4 dated Oct 5, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 4
stated in the proxy; 2 not stated
Average tenure
1.7 years
from year joined
CEO also chairs the board
No
Gregory Summe
Director Age On board Independent Committees Other public boards 2025 pay Source
Gregory Summe
69 2024
2 years
Independent
Nominating and Corporate Governance · Chair
NXP Semiconductors N.V., Avantor, Inc., Wheels Up Experience, Inc. $377,470
Joshua Ofman
62 2026
this year
Not stated None stated None stated Not stated
Sarah Krevans
67 2024
2 years
Independent
Audit Compensation Nominating and Corporate Governance
None stated $322,470
Steven Mizell
66 2024
2 years
Independent
Compensation · Chair
Allegion Plc., Group 1 Automotive, Inc. $329,970
William Chase
58 2024
2 years
Independent
Audit · Chair Compensation Nominating and Corporate Governance
Intellia Therapeutics, Inc. $332,470
Robert Ragusa Leaving at the meeting
66 2024
2 years
Not stated None stated Twist Bioscience Corporation Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

9 disclosed in the proxy filed Apr 28, 2026
Illumina
Amount not stated
2024

Separation and Distribution Agreement with Illumina setting agreements for the Spin-Off and the ongoing relationship.

With the Company Open in proxy
Illumina
stockholder owning 5% or more of our outstanding common stock
Amount not stated

Illumina contributed cash before the Spin-Off to cover 2.5 years of operations (Disposal Funding), which may have to be returned under certain restricted-period transactions.

With the Company Open in proxy
Illumina
Amount not stated
2024

Tax Matters Agreement governing tax rights, responsibilities and obligations after the Distribution.

With the Company Open in proxy
Illumina
Amount not stated
2024

Employee Matters Agreement addressing employment, compensation and benefits matters tied to the Spin-Off.

With the Company Open in proxy
Illumina
stockholder owning 5% or more of our outstanding common stock
Amount not stated
2024

Stockholder and Registration Rights Agreement granting Illumina registration rights and voting arrangements for its shares.

With the Company Open in proxy
Illumina
Amount not stated
January 2016

Supply and commercialization agreement under which the Company pays Illumina a royalty on oncology net sales, with royalties suspended while GRAIL is an Illumina affiliate.

With the Company Open in proxy
Illumina
Amount not stated
February 2019

Two license agreements under which Illumina pays the Company licensing fees, minimum royalties and running royalties.

With the Company Open in proxy
Illumina
$0.2 million and $0.5 million
2025 and 2024

Illumina purchased Galleri tests from the Company.

With the Company Open in proxy
Illumina
stockholder owning 5% or more of our outstanding common stock
Amount not stated
2021

Illumina's 2021 acquisition of GRAIL, in which Illumina issued contingent value rights to GRAIL holders; Illumina retains the CVR obligation after the Spin-Off.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support